GeneFrontier Corp.

GeneFrontier Corp. is a biopharmaceutical company with a focus on antibody technologies, aiming to revolutionize medical breakthroughs in the future. As a member of the Kaneka Group since October 2010, Gene Frontier has been a key player in the microarray and antibody-related sectors. In collaboration with MorphoSys, the company has ventured into the development of antibody drugs known for their precise targeting of disease-related proteins and reduced side effects. Leveraging artificial recombinant human antibody production technology, Gene Frontier is engaged in joint research and licensing initiatives to enhance antibody drug discovery within Japan. The company's commitment to accelerating biopharmaceutical research and development is poised to expand its business domains and capabilities in the field, with the support of Kaneka. Gene Frontier's alignment with Kaneka's vision of "To be more surprised, to Mirai" underscores its dedication to offering unique technologies and services for advancing innovative medicines and diagnostics, thus contributing to 21st-century medical treatments.